Valuation: Seer, Inc.

Capitalization 116M 98.22M 90.69M 85.49M 159M 10.76B 161M 1.06B 417M 5.18B 434M 425M 18.41B P/E ratio 2026 *
-1.9x
P/E ratio 2027 * -1.95x
Enterprise value 116M 98.22M 90.69M 85.49M 159M 10.76B 161M 1.06B 417M 5.18B 434M 425M 18.41B EV / Sales 2026 *
6.97x
EV / Sales 2027 * 5.53x
Free-Float
88.51%
Yield 2026 *
-
Yield 2027 * -
1 day+4.59%
1 week+21.30%
Current month+22.02%
1 month+14.53%
3 months+8.47%
6 months-7.24%
Current year+12.02%
1 week 1.82
Extreme 1.82
2.05
1 month 1.65
Extreme 1.65
2.05
Current year 1.65
Extreme 1.65
2.2
1 year 1.65
Extreme 1.65
2.41
3 years 1.46
Extreme 1.455
5.65
5 years 1.46
Extreme 1.455
54.63
10 years 1.46
Extreme 1.455
86.55
Manager TitleAgeSince
Chief Executive Officer 57 2018-02-28
Director of Finance/CFO 58 2020-04-30
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 68 2024-08-12
Director/Board Member 70 2017-11-30
Director/Board Member 76 2017-11-30
Change 5d. change 1-year change 3-years change Capi.($)
+4.59%+21.30%+3.54%-47.44% 116M
-1.90%-3.31%+26.97%-18.14% 26.14B
-0.34%+0.37%+4.79%-9.44% 6.94B
+2.29%+2.60%+21.90%+41.48% 2.72B
+1.02%+2.52%-2.61%-65.75% 2.23B
-3.66%-3.04%+37.45%+44.55% 1.94B
+1.55%-0.48%+31.92%+30.50% 1.8B
+2.22%-1.93%+141.94%+67.99% 1.67B
-4.29%+12.01%+32.42%+66.56% 1.21B
+0.44%+1.25%-39.83%-48.54% 896M
Average +0.19%+3.46%+25.85%+6.18% 4.57B
Weighted average by Cap. -1.06%+0.20%+25.46%-6.30%

Financials

2026 *2027 *
Net sales 16.6M 14.1M 13.02M 12.27M 22.76M 1.54B 23.16M 153M 59.79M 743M 62.27M 60.97M 2.64B 20.9M 17.75M 16.39M 15.45M 28.66M 1.94B 29.16M 192M 75.28M 936M 78.4M 76.77M 3.33B
Net income -60.3M -51.21M -47.28M -44.57M -82.69M -5.61B -84.12M -554M -217M -2.7B -226M -221M -9.6B -58.7M -49.85M -46.02M -43.39M -80.49M -5.46B -81.89M -539M -211M -2.63B -220M -216M -9.34B
Net Debt - -
Logo Seer, Inc.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
Employees
124
Date Price Change Volume
26-04-16 2.050 $ +4.59% 556,824
26-04-15 1.960 $ +1.03% 358,219
26-04-14 1.940 $ +1.04% 780,478
26-04-13 1.920 $ +13.61% 3,355,427
26-04-10 1.690 $ 0.00% 109,451
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.050
Average target price
-

Quarterly revenue - Rate of surprise